AD treatment strategies in the past 30 years were mainly focused on the pathological hallmarks, i.e., extracellular beta-amyloid (Aβ) accumulation and intraneuronal abnormal tau hyperphosphorylation [11]. The gene discussed is MAPT; the disease is Alzheimer disease.